Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.69 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.53 |
| ▸ | ACLY | P53396 | 3/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788576 | 0.82 | PFKFB3 (1.00) | PFKFB3PFKFB4ACLYMCL1PTGES2 | |
| SCHEMBL787938 | 0.79 | PFKFB3 (0.71) | PFKFB3PFKFB4ACLYPTGES2CCR2 | |
| SCHEMBL9997253 | 0.77 | PFKFB3 (0.63) | PFKFB3ACLYMCL1MEN1KMT2A | |
| SCHEMBL788309 | 0.74 | PFKFB3 (0.61) | PFKFB3PFKFB4ACLYPTGES2 | |
| SCHEMBL28637555 | 0.72 | KMT2A (0.58) | PFKFB3ACLYMCL1MEN1KMT2A | |
| SCHEMBL15508514 | 0.71 | SLC40A1 (0.67) | MEN1KMT2APLAUMETAP2 | |
| SCHEMBL9997964 | 0.71 | FABP4 (0.60) | PFKFB4ACLYMCL1WDR5MEN1 | |
| SCHEMBL2888830 | 0.70 | KDM1A (0.54) | ACLYMCL1MEN1KMT2AMAPT | |
| SCHEMBL9997012 | 0.70 | ALDH1A1 (0.56) | PFKFB4MCL1WDR5MEN1KMT2A | |
| SCHEMBL788372 | 0.69 | PFKFB4 (1.00) | PFKFB3PFKFB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616450-B1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2616450-B1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2018-05-02 | — | — | EP | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| EP-2616450-A2 | SULFONAMIDE COMPOUNDS | Kancera AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| WO-2012035171-A2 | NEW COMPOUNDS | KANCERA AB (SE) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035171-A2 | NEW COMPOUNDS | KANCERA AB (SE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | SULT1A1, STS, ARSA | PFKFB3 952/4885PFKFB4 889/4885ACLY 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.